Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). (Q33386875)

26 July 2017

title

Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). (English)

1 reference

26 July 2017

1 reference

W Koizumi

1

1 reference

26 July 2017

H Takiuchi

2

1 reference

26 July 2017

Y Yamada

3

1 reference

26 July 2017

N Boku

4

1 reference

26 July 2017

N Fuse

5

1 reference

26 July 2017

K Muro

6

1 reference

26 July 2017

Y Komatsu

7

1 reference

26 July 2017

A Tsuburaya

8

1 reference

26 July 2017

publication date

29 October 2009

1 reference

26 July 2017

1 reference

26 July 2017

volume

21

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

1001-1005

1 reference

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP464

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP464

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP464

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP464

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP464

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP464

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP464

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP464

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP464

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP464

Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP464

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDP464

1 reference

release_dunpsspryveutgrmchwlosdxjm

26 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dunpsspryveutgrmchwlosdxjm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference